244 related articles for article (PubMed ID: 12182261)
1. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
Ludwig M; Stapff M; Ribeiro A; Fritschka E; Tholl U; Smith RD; Stumpe KO
Clin Ther; 2002 Jul; 24(7):1175-93. PubMed ID: 12182261
[TBL] [Abstract][Full Text] [Related]
2. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension.
Roca-Cusachs A; Oigman W; Lepe L; Cifkova R; Karpov YA; Harron DW
Acta Cardiol; 1997; 52(6):495-506. PubMed ID: 9542575
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
Farsang C; Garcia-Puig J; Niegowska J; Baiz AQ; Vrijens F; Bortman G
J Hypertens; 2000 Jun; 18(6):795-801. PubMed ID: 10872566
[TBL] [Abstract][Full Text] [Related]
7. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
Manolis AJ; Grossman E; Jelakovic B; Jacovides A; Bernhardi DC; Cabrera WJ; Watanabe LA; Barragan J; Matadamas N; Mendiola A; Woo KS; Zhu JR; Mejia AD; Bunt T; Dumortier T; Smith RD
Clin Ther; 2000 Oct; 22(10):1186-203. PubMed ID: 11110230
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE;
Clin Ther; 2003 May; 25(5):1469-89. PubMed ID: 12867222
[TBL] [Abstract][Full Text] [Related]
9. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
Olsen MH; Wachtell K; Neland K; Bella JN; Rokkedal J; Dige-Petersen H; Ibsen H
Blood Press; 2005; 14(3):177-83. PubMed ID: 16036498
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
Townsend R; Haggert B; Liss C; Edelman JM
Clin Ther; 1995; 17(5):911-23. PubMed ID: 8595643
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
[TBL] [Abstract][Full Text] [Related]
12. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid JL; Rodicio J; Safar M; Eckes L; Rizzini P;
Circulation; 2002 Nov; 106(19):2422-7. PubMed ID: 12417537
[TBL] [Abstract][Full Text] [Related]
13. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension.
Flack JM; Saunders E; Gradman A; Kraus WE; Lester FM; Pratt JH; Alderman M; Green S; Vargas R; Espenshade M; Ceesay P; Alexander J; Goldberg A;
Clin Ther; 2001 Aug; 23(8):1193-208. PubMed ID: 11558858
[TBL] [Abstract][Full Text] [Related]
15. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
Hong SJ; Ahn TH; Baek SH; Cho WH; Jeon HK; Kwan J; Yoon MH; Lee KJ; Lim DS
Clin Ther; 2006 Apr; 28(4):537-51. PubMed ID: 16750465
[TBL] [Abstract][Full Text] [Related]
18. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
19. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
Zanchetti A; Bond MG; Hennig M; Tang R; Hollweck R; Mancia G; Eckes L; Micheli D;
J Hypertens; 2004 Jun; 22(6):1201-12. PubMed ID: 15167456
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
